Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
    • Founders
    • A word from the CEO
  • Antibiotics
    • About
    • Antimicrobial resistance
    • Portfolio
    • The AGIR program
    • Discovery platform
    • Partners
  • Bioactives
    • About
    • Biodiversity
    • Portfolio
    • Platform of Expertise
    • Partners
  • Investor room
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News & events
    • Press releases
    • Events
    • Press coverage
  • Careers
    • Join DEINOVE
    • Open positions
  1. Home
  2. Profile
  3. Executive Committee

Executive Committee

Emmanuel Petiot

Emmanuel Petiot, CEO

EDHEC Business School, École Centrale Paris
Julien Coste

Julien Coste, Director of Finance & Administration

Grenoble business school, Paris-Dauphine University
Georges Gaudriault

Georges Gaudriault, Scientific Director

PhD in molecular pharmacology
Marie Bézenger

Marie Bézenger, Director of Operations

Engineer in Food sciences, PhD in Biochemistry, Cell & Molecular Biology

Sébastien Enault, Head of Business Développement

Engineer in Pharmacology & Biotechnologies

Johane Rinaldi, Head of HR

University of Lyon 2, University of Bordeaux 3

Coralie Martin, Head of Marketing, Communications and Investor Relations

Engineer in Biochemistry, Master in Business

Profile

  • About DEINOVE
  • Board of Directors
  • Executive Committee
  • Founders
  • A word from the CEO

Latest news

06.12.2019

Evolution in DEINOVE's governance

Emmanuel PETIOT will resign as Chief Executive Officer ("CEO") as of December 31, 2019 Dr. Charles...
Corporate
26.09.2019

2019 Half-year consolidated results: Deinove’s progress coming to fruition

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe...
Investors, Corporate
09.07.2019

Issuance of notes convertible into new shares for a maximum amount of €15M. Issuance of a first €2.2 million tranche

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to...
Investors, Corporate
More press releases
  • Contact
  • Location
  • Legal Info
  • Site map
  • Privacy Policy

Profile

  • About DEINOVE
  • Board of Directors
  • Executive Committee
  • Founders
  • A word from the CEO

Antibiotics

  • About
  • Antimicrobial resistance
  • Portfolio
  • The AGIR program
  • Discovery platform
  • Partners

Bioactives

  • About
  • Biodiversity
  • Portfolio
  • Platform of Expertise
  • Partners

Investor room

  • Corporate governance
  • DEINOVE Shares
  • Financial Calendar
  • Documentation Center
  • Press releases
  • Investor relations

Careers

  • Join DEINOVE
  • Open positions

News & events

  • Press releases
  • Events
  • Press coverage

Downloads

  • Investor presentations
  • Analyst Coverage
  • Financial Reports

Follow us

Stay in touch

Subscribe to our newsletter

Contact us

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home